Search Results
Your search for ,WHo matches 20700 pages
Showing 14701 - 14750Poor Understandability of Dense Breast Notifications Sent to Women Following Screening Mammography
In a study published by Kressin et al in JAMA, Nancy R. Kressin, PhD, of the Veterans Affairs Boston Healthcare System, Boston University School of Medicine, and colleagues examined the content, readability, and understandability of dense breast notifications sent to women following screening...
New Study Suggests Cholesterol Levels, Not Statins, Influence Colorectal Cancer Risk
Long-term use of the cholesterol-lowering drugs statins does not appear to decrease a patient’s risk of colorectal cancer, suggests a new, large case-control study from Penn Medicine published by Mamtani et al in PLOS Medicine. The observational analysis of over 100,000 patients’...
A Critical Analysis of Early Bladder Cancer Recurrence After Laparoscopic Radical Cystectomy
Although laparoscopic radical cystectomy and robotic-assisted radical cystectomy continue to grow in popularity and are successful in the treatment of bladder cancer, they are still considered experimental approaches. Using data collected by the Section of Uro-Technology of the European Association ...
ASCO Adapts CCO Guideline on Selection of Optimal Adjuvant Therapy for Breast Cancer
ASCO has adapted a Clinical Care Ontario (CCO) clinical practice guideline on the selection of optimal adjuvant chemotherapy for early breast cancer and adjuvant targeted therapy for HER2-positive breast cancer, as reported in the Journal of Clinical Oncology. The adaptation was based on review by...
Donor Epstein-Barr Virus Status Affects Risk for Graft-vs-Host Disease but Not Survival in Acute Leukemia After HSCT
Positive donor Epstein-Barr virus (EBV) serostatus increases the risk for graft-vs-host disease but does not affect relapse-free or overall survival among patients with acute leukemia receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT), according to a study from the Acute...
Solid Organ Transplant Recipients With Preexisting Malignancies in Remission May Be More Likely to Die, Develop New Cancers
Patients who had cancer before receiving an organ transplant were more likely to die of any cause, die of cancer, or develop a new cancer than organ recipients who did not previously have cancer, a new study published by Acuna et al in the journal Transplantation has found. However, the increased...
FDA Approves Cabozantinib in Patients With Renal Cell Carcinoma Who Have Received Prior Antiangiogenic Therapy
On April 25, 2016, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx) tablets for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. Cabozantinib is a dual tyrosine kinase inhibitor of MET and VEGFR2. The...
FDA Grants Breakthrough Designation to Nivolumab in Squamous Cell Carcinoma of the Head and Neck
On April 25, 2016, the U.S. Food and Drug Administration (FDA) granted breakthrough therapy designation to the anti–programmed death 1 antibody nivolumab (Opdivo) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck that previously received...
Amplification of 9p24.1 Associated With Advanced Stage and Poorer Outcome in Classic Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Roemer et al identified PD-L1 (programmed cell death ligand 1) and PD-L2 genetic alterations in patients with classic Hodgkin lymphoma, finding that 9p24.1 amplification was common and associated with advanced-stage disease and poorer...
Blue Ribbon Panel to Help Guide Cancer Moonshot Initiative
As described in the full report on page 39, the National Cancer Institute (NCI) announced a Blue Ribbon Panel of experts and advocates who will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National Cancer Moonshot Initiative. Members of the research community and...
Severe Adverse Event Clusters Identified Using NCI Common Terminology Criteria
Using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE), researchers from Columbia University, New York, and Fred Hutchinson Cancer Research Center, Seattle, identified six severe adverse event clusters in patients with advanced prostate cancer. The clusters...
Earlier Hospice Enrollment, Avoiding ICU Admissions, and Not Dying in the Hospital Associated With Perceptions of Better End-of-Life Care
Three measures of aggressive end-of-life care “were associated with relatively large differences in family member–reported quality ratings for end-of-life care and a lower likelihood that patients with advanced-stage cancer received care congruent with their preferences,” according to a study in...
Expect Questions About Potential Trade-Offs of Contralateral Prophylactic Mastectomy
Women who were diagnosed with breast cancer and had contralateral prophylactic mastectomy had only marginal improvement in psychosocial well-being, such as feeling confident and emotionally healthy, according to a study published in the Journal of Clinical Oncology.1 Those who also had breast...
Quality-of-Life Benefits of Contralateral Prophylactic Mastectomy May Be Too Small to Be Clinically Meaningful
Women diagnosed with breast cancer who chose contralateral prophylactic mastectomy reported improvement in psychosocial well-being and breast satisfaction, but “the magnitude of the effect may be too small to be clinically meaningful,” according to a study in the Journal of Clinical Oncology.1...
Larry W. Kwak, MD, PhD, Awarded Ho-Am Prize in Medicine
Physician and scientist Larry W. Kwak, MD, PhD, Director of City of Hope’s Toni Stephenson Lymphoma Center, has been awarded the 2016 Ho-Am Prize in Medicine, which recognizes people of Korean heritage who have made impressive contributions in clinical and research areas that contributed to the...
Raising Awareness of Medullary Thyroid Carcinoma
I’m used to having bumps and cysts pop up on my body, so when I felt a lump on the front of my throat, just below my Adam’s apple, I brushed it off. But when it was still there 6 months later, I became concerned and decided to see an ear, nose, and throat specialist. He performed a fine-needle...
Susannah Koontz, PharmD, BCOP, FHOPA, Named HOPA President-Elect for 2016–2017 Term
Susannah Koontz, PharmD, BCOP, FHOPA, took office as President-Elect of the Hematology/Oncology Pharmacy Association (HOPA) at the recent 12th HOPA Annual Conference, held March 16–19 in Atlanta, Georgia. Dr. Koontz will serve as President-Elect for the 2016–2017 term and assume the office of...
Radiation: Myths, Facts, Dangers and Benefits
For many, the word “radiation” conjures up images of mushroom clouds and the nightmarish nuclear disaster at Chernobyl. It also brings to mind those pesky dental x-rays and lifesaving cancer treatments. However, to most people, radiation is a mysterious invisible power to be feared and embraced...
Immunotherapy Could Be the Wave of the Future, but Problems and Challenges Cannot Be Ignored
Immunotherapy is on its way. A few agents have already been approved: ipilimumab (Yervoy) in 2011 for melanoma; nivolumab (Opdivo) in 2015 for non–small cell lung cancer (NSCLC) and then later that year for renal cell carcinoma; and pembrolizumab (Keytruda) for NSCLC. In addition, many clinical...
Supportive Care in the Older Adult With Cancer: What You Need to Know
The median age of patients at the first diagnosis of cancer in the United States is 65 years, and the majority of patients with cancer are older adults.1 As we have learned from previous articles in this series, older patients with cancer require more complex care. Older adults are more likely to...
Praise for the ACS/ASCO Breast Cancer Survivorship Care Guideline
The recent publication of the American Cancer Society (ACS)/ASCO breast cancer survivorship care guideline is a tremendous contribution to the literature and should provide a roadmap for providers who care for patients with a history of breast cancer for years to come.1,2 The guideline, reported by ...
ACS/ASCO Breast Cancer Survivorship Care Guideline
The American Cancer Society (ACS) and ASCO have issued a Breast Cancer Survivorship Care guideline, published jointly in the Journal of Clinical Oncology and CA: A Cancer Journal for Clinicians.1,2 The guideline recommendations were formulated by a multidisciplinary expert work group and are based...
Johns Hopkins Launches Immunotherapy Center With $125 Million Gift
A new institute studying immunology was announced on March 29 at Johns Hopkins by Vice President Joe Biden, Michael R. Bloomberg, and more than a dozen additional supporters of this initiative. Embracing the Vice President’s “moonshot” initiative to cure cancer, the new Bloomberg–Kimmel Institute...
2016 Special Awards: Researchers and Scientists Recognized for Significant Contributions to Cancer Care
Researchers, patient advocates, and global oncology community leaders dedicated to enhancing cancer prevention, treatment, and patient care will be honored with ASCO’s highest honor, its Special Awards, during the 2016 ASCO Annual Meeting. Among this year’s awardees are a lung cancer luminary who...
AACR 2016: Genomic Variants May Influence Risk for Breast Cancer After Chest Radiotherapy to Treat Childhood Cancer
Among females who received radiotherapy to the chest as part of treatment for a childhood cancer, those who had either of two specific genetic variants were at significantly higher risk of developing breast cancer later in life, according to research presented by Morton et al at the 2016 AACR...
AACR 2016: Cologuard Detected Colorectal Cancer in Previously Unscreened Patients
A noninvasive colorectal cancer-screening test detected the disease in patients who had previously avoided more invasive screening measures, according to research presented by Prince et al at the 2016 AACR Annual Meeting (Abstract LB-296). The study of nearly 400 patients revealed four patients...
Blue Ribbon Panel to Help Guide National Cancer Moonshot Initiative
On April 4, 2016, The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), announced a Blue Ribbon Panel of scientific experts, cancer leaders, and patient advocates that will inform the scientific direction and goals at NCI of Vice President Joe Biden’s National Cancer ...
Updates on Elotuzumab in Multiple Myeloma Show Persistence of Benefit
Studies presented at the 2015 ASH Annual Meeting bolstered support for elotuzumab (Empliciti) given in combination with lenalidomide (Revlimid) for the treatment of multiple myeloma. Elotuzumab is an immunostimulatory monoclonal antibody. It has a dual mechanism of action, directly activating...
Expert Point of View: Thierry Facon, MD
Thierry Facon, MD, of Lille University Hospital in France, spoke to The ASCO Post about the preliminary results of the pembrolizumab studies. Dr. Facon cautioned that a response rate of 76% overall “is not so impressive,” given about 65% of patients respond to lenalidomide/dexamethasone alone....
Pembrolizumab Looks Promising in Multiple Myeloma
Monoclonal antibodies targeting the programmed cell death protein (PD-1) receptor look promising in multiple myeloma, according to early reports presented at the 2015 ASH Annual Meeting and Exposition. Early signs of activity in heavily pretreated patients may indicate that, as in solid tumors,...
ASCO Endorses Cancer Care Ontario Guideline on Active Surveillance for Management of Localized Prostate Cancer
As reported by Ronald C. Chen, MD, MPH, of the University of North Carolina at Chapel Hill, and colleagues in the Journal of Clinical Oncology, ASCO has endorsed, with qualifications, the 2015 Cancer Care Ontario (CCO) guideline on active surveillance for management of localized prostate cancer....
CDX2 in Stage II Colon Cancer: Ready for Prime Time?
In a recent issue of The New England Journal of Medicine, Dalerba et al published an impressive article describing a novel bioinformatics approach to identifying new prognostic and predictive biomarkers in patients with stage II and III colon cancer (see summary in this issue of The ASCO Post).1...
City of Hope Awarded NCI Research Grant for Potential Acute Myeloid Leukemia Drug
A City of Hope research team led by Steven T. Rosen, MD, City of Hope’s Provost and Chief Scientific Officer, has been awarded a $2.3 million Research Project Grant (R01) from the National Cancer Institute (NCI) to fund studies associated with a phase I/II clinical trial in relapsed/refractory...
Transcription Factor CDX2 May Be a Prognostic Biomarker in Stage II and III Colon Cancer
In a study reported in The New England Journal of Medicine, Piero Dalerba, MD, of Columbia University, and colleagues found that absence of the transcription factor CDX2 was prognostic for poor outcome in patients with stage II and III colon cancer vs cancers with CDX2 expression.1 However,...
Neoadjuvant Endocrine Therapy Vastly Underutilized by U.S. Clinicians
Neoadjuvant endocrine therapy in the management of breast cancer is woefully underutilized by U.S. clinicians, according to advocates of this approach who made their case at the 2016 Miami Breast Cancer Conference.1 In postmenopausal women with estrogen receptor–rich tumors, neoadjuvant endocrine...
Expert Point of View: Patrick Borgen, MD
Patrick Borgen, MD, Chair of the Department of Surgery at Maimonides Medical Center, Brooklyn, New York, called these findings important and clinically relevant. “This study was an enormous undertaking, to review the detailed clinical records on 3,000 consecutive patients. It’s an amazing and...
In Ductal Carcinoma in Situ, Benefit of Wider Margins Tied to Radiation Use
The relationship between margin width and risk of recurrence after breast-conserving surgery for ductal carcinoma in situ depends on the use of radiation, according to a surgical oncologist who sought to determine the optimal margin width in these patients.1 “Positive margins are associated with an ...
Liquid Biopsies Predict Treatment Response and Survival in Gynecologic Cancers
A new study has demonstrated for the first time that personalized circulating tumor DNA (ctDNA) biomarkers in gynecologic cancers can detect the presence of residual tumor earlier than currently used serum and imaging studies.1,2 According to the data, undetectable levels of ctDNA at the completion ...
Expert Point of View: Kian Behbakht, MD
Kian Behbakht, MD, Professor of Gynecologic Oncology at the University of Colorado School of Medicine, Aurora, said that the study underscored the surgical importance of getting to no visible residual disease in ovarian cancer. “Based on today’s data,” said Dr. Behbakht, “it seems as though it’s...
AACR 2016: Delays in Radiation Therapy Increase Chance of Breast Tumor Development in Women Treated for DCIS
Women who underwent treatment for ductal carcinoma in situ (DCIS) were at higher risk of developing malignant breast tumors if they did not receive timely radiation therapy as part of their treatment, according to a study presented by Liu et al at the 2016 AACR Annual Meeting (Abstract 2576). DCIS ...
AACR 2016: Certain Oral Bacteria May Be Associated With Increased Pancreatic Cancer Risk
The presence of two species of bacteria linked to periodontal disease in the mouths of healthy individuals was associated with an increased risk of subsequently developing pancreatic cancer, according to research presented by Fan et al at the 2016 AACR Annual Meeting (Abstract 4350). ...
Interim FDG-PET Response-Adapted Therapy May Be of Benefit in Hodgkin Lymphoma
In a phase II US Intergroup trial (Southwest Oncology Group S0816) reported in the Journal of Clinical Oncology, Press et al found that early interim fluorodeoxyglucose positron-emission tomography (FDG-PET) to guide response-adapted therapy resulted in progression-free survival substantially...
Study Supports Initial Attempt at Debulking Surgery in Stage IIIC Ovarian, Fallopian Tube, and Peritoneal Carcinoma
In a study exploring the effect of primary debulking surgery in women with bulky stage IIIC ovarian, fallopian tube, and primary peritoneal cancers, cytoreduction to no gross residual disease was associated with the best survival outcomes.1 Cytoreduction to 1 to 10 mm of residual disease was also...
Expert Point of View: Kristin Zorn, MD
Kristin Zorn, MD, Associate Professor and Director of Gynecologic Oncology at the University of Arkansas for Medical Sciences, Little Rock, said that the study’s data confirm the importance of other homologous recombination genes in these defects, not just BRCA1 and BRCA2. “I think this really...
Genetic Testing in Women With Ovarian Cancer Helps to Determine Prognosis
A new study suggests that homologous recombination deficiency may have significant prognostic implications for patients with ovarian cancer, highlighting the importance of genetic testing in this population.1 According to the data, patients with ovarian cancer who have mutations in genes affecting...
Physicians as Champions for Quality Improvement
Interest in quality measurement and improvement was once primarily a concern of regulators, insurers, and consumer advocates. Today, quality improvement is front and center in health care—a continuous mission requiring the efforts of everyone on the health-care team. At the recent ASCO Quality Care ...
Benefits and Risks of Transplantation: The Changing Therapeutic Paradigm for Multiple Myeloma
Although high-dose chemotherapy plus autologous transplantation has been a standard of care in the treatment of younger patients with newly diagnosed multiple myeloma, the advent of effective novel agents for the cancer over the past 15 years has raised the question of whether transplantation, with ...
Novel Strategies Emerging for Triple-Negative Breast Cancer
Compelling hypotheses are emerging about the mechanisms driving triple-negative breast cancer, and they are driving drug development in this area, according to Joyce O’Shaughnessy, MD, Celebrating Women Chair of Breast Cancer Research at Baylor Charles A. Sammons Cancer Center. She is also Medical...
AACR 2016: Palbociclib Shows Antiproliferative Activity in Early-Stage Breast Cancer
The molecularly targeted therapeutic palbociclib (Ibrance) was effective in slowing the multiplication of cancer cells in patients diagnosed with early-stage breast cancer who received no prior therapy, according to data from a phase II clinical trial presented by Arnedos et al at the 2016 AACR...
AACR 2016: 5-Year Survival Rates for Patients With Metastatic Melanoma Treated With Nivolumab Much Higher Than Historical Rates
More than a third of metastatic melanoma patients (34%) who received the anti–programmed cell death protein 1 (PD-1) immunotherapeutic nivolumab (Opdivo) in a phase I clinical trial are still alive 5 years after starting treatment, according to research presented by Hodi et al at the 2016...
